<DOC>
	<DOC>NCT00133874</DOC>
	<brief_summary>The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.</brief_summary>
	<brief_title>Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo</brief_title>
	<detailed_description>A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative, Phase III Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo.</detailed_description>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Impetigo</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Inclusion criteria: Must have primary impetigo with total lesion area being 100 square centimeters or less. Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures. Any signs and symptoms of systemic infection. Any serious underlying disease that could be imminently life threatening.</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>topical antibacterial</keyword>
	<keyword>topical antibiotic</keyword>
	<keyword>impetigo</keyword>
</DOC>